Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical pharmacology and therapy

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpt.812PMID 28791698
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Case-Control Study

  2020cited by this paper
• Genetic Study

  2020cited by this paper
• Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families

  2017influential reference
• Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption

  2016cited by this paper
• Arzneiverordnungs-Report 2016

  2016cited by this paper
• OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics

  2016cited by this paper
• Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1.

  2015cited by this paper
• Unstirred Water Layers and the Kinetics of Organic Cation Transport

  2015cited by this paper
• Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1

  2015influential reference
• Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.

  2014cited by this paper
• OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

  2014cited by this paper
• Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.

  2013cited by this paper
• OCT1 genetic variants influence the pharmacokinetics of morphine in children.

  2013cited by this paper
• Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

  2013influential reference
• The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1.

  2012cited by this paper
• Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol

  2011cited by this paper
• Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron

  2010cited by this paper
• The use of beta agonists and the risk of death and near death from asthma.

  2009cited by this paper
• Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

  2009influential reference
• Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study

  2009cited by this paper
• Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

  2007cited by this paper
• Does personality predict mortality? Results from the GAZEL French prospective cohort study.

  2007cited by this paper
• Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

  2006cited by this paper
• Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.

  2006cited by this paper
• Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.

  2004cited by this paper
• Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1

  2003cited by this paper
• Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin

  2002cited by this paper
• Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.

  2002cited by this paper
• Relation of cigarette smoking to 25-year mortality in middle-aged men with low baseline serum cholesterol: the Chicago Heart Association Detection Project in Industry.

  2002cited by this paper
• Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry.

  1999cited by this paper
• Cloning and functional expression of a human liver organic cation transporter.

  1997cited by this paper
• End of the New Zealand asthma mortality epidemic.

  1995cited by this paper
• Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic.

  1995cited by this paper
• Fenoterol metabolism in man: sulphation versus glucuronidation.

  1994cited by this paper
• A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol.

  1993cited by this paper
• A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor.

  1993cited by this paper
• The use of beta-agonists and the risk of death and near death from asthma.

  1992cited by this paper
• Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.

  1992cited by this paper
• The Use of β-Agonists and the Risk of Death and near Death from Asthma

  1992cited by this paper
• Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.

  1989cited by this paper
• Heart rate and cardiovascular mortality: the Framingham Study.

  1987cited by this paper
• The Framingham study.

  1976cited by this paper
• Letter: Medical audit.

  1975cited by this paper

• Ex vivo perfusion model of mouse liver and its application to analyze the effects of OCT1 deficiency

  2025cites this paper
• The divergent roles of tryptophans W354 and W217 in OCT1 transport: Similar localization, distinct functions

  2025cites this paper
• Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies.

  2025cites this paper
• Substrate-specific effects point to the important role of Y361 as part of the YER motif in closing the binding pocket of OCT1

  2025cites this paper
• Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail

  2025cites this paper
• Substrate Specificity of the Organic Cation Transporters MATE1 and MATE2K and Functional Overlap with OCT1 and OCT2

  2025cites this paper
• Drug Transporters Polymorphism Among Indonesian Population: A Review

  2025cites this paper
• The organic cation transporters 1 and 2 mediate ethanolamine cellular efflux and control systemic phosphatidylethanolamine level

  2025cites this paper
• Comprehensive characterization of the OCT1 phenylalanine-244-alanine substitution reveals highly substrate-dependent effects on transporter function

  2024cites this paper
• Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier

  2024cites this paper
• The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.

  2024cites this paper
• Sex‐Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans

  2024cites this paper
• An extended substrate spectrum of the proton organic cation antiporter and relation to other cation transporters

  2024cites this paper
• Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes

  2023cites this paper
• Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2

  2023cites this paper
• Combined and independent effects of OCT1 and CYP2D6 on the cellular disposition of drugs.

  2023cites this paper
• The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics

  2023cites this paper
• Structural basis of promiscuous substrate transport by Organic Cation Transporter 1

  2023cites this paper
• Stereoselectivity in Cell Uptake by SLC22 Organic Cation Transporters 1, 2, and 3

  2023cites this paper
• Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2

  2023cites this paper
• A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes

  2023cites this paper
• Genetic variation in organic cation transporters and considerations in drug development

  2023cites this paper
• Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1

  2022cites this paper
• Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers

  2022cites this paper
• Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.

  2022cites this paper
• Special Section on New Era of Transporter Science — Minireview Emerging Roles of the Human Solute Carrier 22 Family S

  2022cites this paper
• Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development

  2022influential citation
• Relationships between Inhibition, Transport and Enhanced Transport via the Organic Cation Transporter 1

  2022cites this paper
• The Role of SLC22A1 and Genomic Ancestry on Toxicity during Treatment in Children with Acute Lymphoblastic Leukemia of the Amazon Region

  2022cites this paper
• Cloning and Functional Characterization of Dog OCT1 and OCT2: Another Step in Exploring Species Differences in Organic Cation Transporters

  2022cites this paper
• Drug Transport—Uptake

  2021cites this paper
• Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins

  2021cites this paper
• Cellular Uptake of Psychostimulants – Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?

  2021cites this paper
• Expansion of Knowledge on OCT1 Variant Activity In Vitro and In Vivo Using Oct1/2−/− Mice

  2021influential citation
• Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.

  2021cites this paper
• Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1

  2021cites this paper
• Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters

  2021cites this paper
• General Overview of Organic Cation Transporters in Brain.

  2021cites this paper
• Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?

  2021influential citation
• Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models

  2021cites this paper
• Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced in vitro testing

  2021influential citation
• Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity

  2021cites this paper
• Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1

  2021influential citation
• Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport

  2021cites this paper
• Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients

  2021cites this paper
• OCT1 Polyspecificity—Friend or Foe?

  2021cites this paper
• Substrates and Inhibitors of Organic Cation Transporters (OCTs) and Plasma Membrane Monoamine Transporter (PMAT) and Therapeutic Implications.

  2021cites this paper
• Role of Membrane Transporters in Drug Disposition

  2021cites this paper
• Overlap and Specificity in the Substrate Spectra of Human Monoamine Transporters and Organic Cation Transporters 1, 2, and 3

  2021cites this paper
• Emerging Roles of the Human Solute Carrier 22 Family

  2021cites this paper
• Molecular basis for stereoselective transport of fenoterol by the organic cation transporters 1 and 2.

  2021cites this paper
• Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology

  2020cites this paper
• Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts

  2020cites this paper
• Organic Cation Transporters in Health and Disease

  2020cites this paper
• Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions Organic Cation Transporter 1 and 3 Contribute to the High Accumulation of Dehydrocorydaline in the Heart s

  2020cites this paper
• Organic Cation Transporter 1 and 3 Contribute to the High Accumulation of Dehydrocorydaline in the Heart

  2020cites this paper
• Principles of Pharmacogenomics

  2019cites this paper
• In Vitro to In Vivo Extrapolation of Pharmacokinetic Drug Interactions between Clarithromycin and Ranitidine with Trospium Chloride to Evaluate Probe Drug Characteristics for P-glycoprotein and Organic Cation Transporter Functions in Human Inauguraldissertation

  2019cites this paper
• Short Communication Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A

  2019influential citation
• Short Communication Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A

  2019influential citation
• Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A

  2019influential citation
• Erweiterte Charakterisierung substratspezifischer Effekte genetischer Polymorphismen im organischen Kationentransporter OCT1

  2019influential citation
• Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake

  2019cites this paper
• Opioids as substrates and inhibitors of the genetically highly variable organic cation transporter OCT1.

  2019cites this paper
• The human organic cation transporter OCT1 and its role as a target for drug responses

  2019cites this paper
• Short Communication Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A

  2019influential citation
• Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions

  2019cites this paper
• Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

  2018cites this paper
• Elucidation of Substrate Binding Interactions for Human Organic Cation Transporters 1 (SLC22A1) and 2 (SLC22A2) Using In Silico Homology Modeling in Conjunction with In Vitro Site-Directed Mutagenesis and Kinetic Analysis

  2018cites this paper
• OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil

  2018cites this paper
• Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions

  2018cites this paper
• Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1)

  2018cites this paper
• Enantioselective Drug Recognition by Drug Transporters

  2018cites this paper
• Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

  2018cites this paper
• Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

  2018cites this paper
• Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine

  2017cites this paper